How India Exports Linagliptin to the World

As of March 2026, the FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for linagliptin, indicating a competitive generic market. Recent approvals include those granted in January 2026. No import alerts specific to linagliptin have been issued by the FDA, suggesting compliance with U.S. regulatory standards. The regulatory pathway for linagliptin involves submission of an ANDA, demonstrating bioequivalence to the reference listed drug. With 118 active Indian exporters and a repeat buyer rate of 62.6%, the U.S. market presents significant opportunities for Indian manufacturers.

The European Medicines Agency (EMA) granted marketing authorization for linagliptin-containing products, such as Jentadueto, on 24 November 2016. The UK's Medicines and Healthcare products Regulatory Agency (MHRA) aligns with EMA standards, ensuring consistent regulatory requirements across Europe. Compliance with EU Good Manufacturing Practice (GMP) guidelines is mandatory for market access.

Linagliptin is included in the 22nd edition of the WHO Model List of Essential Medicines, underscoring its importance in diabetes management. While not listed in the WHO Prequalification Programme, linagliptin must meet pharmacopoeial standards such as those outlined in the United States Pharmacopeia (USP) and the British Pharmacopoeia (BP) to ensure quality and efficacy.

In India, linagliptin is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensation. The National Pharmaceutical Pricing Authority (NPPA) has not set a ceiling price for linagliptin, allowing market-driven pricing. Export of linagliptin necessitates a No Objection Certificate (NOC) from the Directorate General of Foreign Trade (DGFT), ensuring compliance with export regulations.

The primary patent for linagliptin expired in 2022, leading to increased generic competition. This has resulted in a diversified market with multiple manufacturers offering generic versions, enhancing accessibility and affordability.

In June 2025, the NPPA issued guidelines to streamline the approval process for generic drugs, potentially benefiting linagliptin manufacturers. In September 2025, the FDA approved a new generic version of linagliptin, further intensifying market competition. In December 2025, the EMA updated its guidelines on bioequivalence studies, impacting the approval process for generic linagliptin products. In February 2026, the WHO released a report emphasizing the need for stringent quality control in the production of antidiabetic medications, including linagliptin. In March 2026, the CDSCO announced a crackdown on substandard pharmaceutical exports, highlighting the importance of compliance for linagliptin exporters.

These developments reflect a dynamic regulatory environment, necessitating continuous monitoring by stakeholders involved in the export and distribution of linagliptin.

India's pharmaceutical industry heavily relies on China for Key Starting Materials (KSMs) and Active Pharmaceutical Ingredients (APIs). Over 70% of APIs used by Indian manufacturers are imported, primarily from China. This dependency poses significant risks, as any disruption in Chinese supply chains can directly impact Indian pharmaceutical production. For instance, in 2022, lockdowns in Shanghai delayed shipments of oncology drug intermediates, leading to rationing of inventories by downstream manufacturers.

To mitigate such vulnerabilities, the Indian government introduced the Production Linked Incentive (PLI) scheme, aiming to bolster domestic API and KSM manufacturing. This initiative seeks to reduce reliance on imports by incentivizing local production through financial support and infrastructure development. (pharmanow.live)

The Linagliptin export market from India exhibits a high degree of supplier concentration. The top five exporters account for 76.3% of the total export value, with BETA DRUGS LIMITED alone contributing 65.1%. Such concentration poses a single-source risk; any operational or financial issues within these key suppliers could disrupt the entire supply chain.

The PLI scheme is designed to address these risks by promoting diversification and encouraging more manufacturers to enter the API and KSM production space. By providing financial incentives and support, the scheme aims to reduce dependency on a limited number of suppliers and enhance the resilience of the pharmaceutical supply chain. (pharmanow.live)

Global shipping routes, including the Red Sea and the Strait of Hormuz, are critical for the transportation of pharmaceutical products. Geopolitical tensions in these regions can lead to shipping delays and increased costs. Additionally, U.S.-China trade tensions have highlighted the risks associated with over-reliance on Chinese suppliers for APIs and KSMs. A study released in October 2025 revealed that 41% of key starting materials for U.S.-approved medicines are sourced solely from China, underscoring the potential for supply chain disruptions.

Regulatory agencies have also noted the impact of supply chain vulnerabilities. In February 2026, the European Medicines Agency (EMA) published a statement from the Drug Shortages Global Regulatory Working Group, emphasizing the need for enhanced transparency and proactive risk assessments to mitigate drug shortages.

• Diversify Supplier Base: Encourage the development of multiple Linagliptin suppliers to reduce dependency on a few key exporters.

• Enhance Domestic Production: Leverage the PLI scheme to boost local manufacturing of APIs and KSMs, decreasing reliance on imports.

• Strengthen Supply Chain Monitoring: Implement robust systems to monitor geopolitical developments and shipping routes, allowing for proactive adjustments to logistics strategies.

• Develop Alternative Shipping Routes: Identify and establish alternative shipping pathways to mitigate risks associated with geopolitical tensions in critical maritime regions.

• Engage in Regulatory Collaboration: Work closely with international regulatory bodies to stay informed about potential shortages and collaborate on solutions to maintain supply chain stability.

RISK_LEVEL: MEDIUM